报价延迟最少15分钟:2026/02/28 16:31 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.02 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.53/-0.16
|
|
企业价值
1.24B
|
| 资产负债 |
|
每股账面净值
0.46
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
